Page last updated: 2024-10-31

clorgyline and Parkinsonian Disorders

clorgyline has been researched along with Parkinsonian Disorders in 2 studies

Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takahata, K1
Shimazu, S1
Yoneda, F1
Ogawa, M1
Iida, Y1
Saji, H1
Prat, G1
PĂ©rez, V1
Rubi, A1
Casas, M1
Unzeta, M1

Other Studies

2 other studies available for clorgyline and Parkinsonian Disorders

ArticleYear
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease

2003
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:4

    Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors

2000